Joshua Reginald Salmans

Title: Innovations by Joshua Reginald Salmans

Introduction

Joshua Reginald Salmans is an accomplished inventor based in South San Francisco, California. He holds two patents that focus on advancements in the detection and treatment of transthyretin-related disorders. His work has significant implications for diagnosing and managing diseases associated with transthyretin accumulation.

Latest Patents

One of Salmans' latest patents is titled "Methods of detecting transthyretin." This invention provides methods for detecting transthyretin (TTR) using a capture antibody and a reporter antibody. The capture antibody preferentially binds to misfolded TTR over the native tetrameric form of TTR. It specifically targets an epitope within amino acid residues 89-97 or 101-109 of TTR. Examples of suitable capture antibodies include 9D5 and 18C5. These methods can be utilized for diagnosing diseases associated with TTR accumulation, such as TTR amyloidosis, and for monitoring the efficacy of TTR therapies.

Another significant patent by Salmans is related to "Anti-transthyretin antibodies." This invention provides antibodies that specifically bind to transthyretin (TTR). These antibodies can be used for treating or preventing diseases associated with TTR accumulation. They are also useful for diagnosing TTR amyloidosis and inhibiting the aggregation of TTR, as well as for monitoring the effectiveness of TTR therapies.

Career Highlights

Throughout his career, Joshua Salmans has worked with notable companies, including Novo Nordisk A/S. His contributions to the field of biomedical research have been recognized for their potential to improve patient outcomes in TTR-related disorders.

Collaborations

Salmans has collaborated with several professionals in his field, including Svetlana Alexander and Robin McDaid Barbour. These collaborations have likely enriched his research and contributed to the development of his innovative patents.

Conclusion

Joshua Reginald Salmans is a notable inventor whose work in transthyretin detection and treatment has the potential to significantly impact medical diagnostics and therapies. His patents reflect a commitment to advancing healthcare solutions for TTR-related conditions.